Abstract #1374

IDH-1 Mutation and Non-Enhancing Component of Glioblastoma

Daniel M Fountain¹, Timothy J Larkin², Natalie R Boonzaier², Jiun-Lin Yan², and Stephen J Price²

¹The Brain Tumour Imaging Laboratory, Division of Neurosurgery, University of Cambridge, Cambridge, United Kingdom, ²Division of Neurosurgery and Wolfson Brain Imaging Centre, The Brain Tumour Imaging Laboratory, Cambridge, United Kingdom

IDH-1 mutated glioblastoma is associated with improved survival, and greater sensitivity to further resection of non-enhancing disease than IDH-1 wild-type. We used structural, diffusion tensor, perfusion and spectroscopic imaging data in a mixed model across the peritumoral region in 54 patients. Applying a mixed model methodology across three levels of data resolution, we demonstrated that IDH-1 mutated tumors demonstrated raised choline and lowered glutamate and glutamine compared to IDH-1 wild-type. The findings provided an AUC of 0.943 when combined with age. We hypothesised this results in greater sensitivity to treatment and reduced excitotoxicity, thus explaining their relatively superior prognosis.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.